Clinical Trial ChallengesThe Duravelo-2 study has 11 active sites, well below the target enrollment of 200 sites, raising concerns about whether BCYC can efficiently reach its enrollment targets.
Financial PerformanceDowngrading BCYC stock from Buy to Neutral ahead of the company's ESMO updates, as no significant share price movement is anticipated.
Market CompetitionPadcev, the current nectin-4 market leader, has significantly penetrated the market, making it challenging for BT-8009 to displace it as the standard of care.